What’s special about DMX-200?
New use of known drugs:
Both irbesartan and propagermanium have well known safety profiles, as they have each been used safely for many years. This minimizes the safety risk of DMX-200 to patients.
Doesn’t take patients off standard of care:
DMX-200 does not require patients to stop taking irbesartan, which stabilizes their blood pressure and decreases proteinuria. Taking patients off standard of care risks potentially detrimental consequences relating to uncontrolled blood pressure. Therefore, patients get to stay on their well-known and safe blood pressure controlling drug and get the additional proteinuria benefit of DMX-200.
Current standard of care drugs, such as irbesartan, reduce the leakage of protein into the urine. However, the reduction of kidney function continues unless the damage caused by inflammation is controlled, leaving many treatment options ineffective. By adding the anti-inflammatory drug propagermanium to irbesartan, DMX-200 aims to combat this inflammation, preserving kidney function.
Supported by Receptor-HIT platform:
DMX-200 was identified using our Receptor-HIT platform. In our meeting with the FDA, they confirmed the relevance of heteromers to drug development, which is the basis of our Receptor-HIT platform and DMX-200.
Orphan Drug Designation for Focal Segmental Glomerulosclerosis (FSGS):
Dimerix has secured orphan drug designation for DMX-200 in FSGS in the US. Current treatment options for FSGS are limited and have significant side effects, meaning there is a desperate need for safe treatments. Through the orphan drug program, DMX-200 will be have access to a number of regulatory and financial incentives, potentially meaning shorter trials and lower costs compared to other therapies.